Showing results (21-30 of 45) with videos related to
Sort By:
Pageof 5
Blood|April 24, 2004
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myelomaChristopher A Maxwell, Erik Rasmussen, Fenghuang Zhan, et al.British Journal of Cancer|February 5, 2020
Inhibition of the deubiquitinase USP10 induces degradation of SYKJing Yang, Chengcheng Meng, Ellen Weisberg, et al.Blood|September 26, 2008
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemiaSophia Adamia, Amanda A Reichert, Hemalatha Kuppusamy, et al.Journal of Cellular and Molecular Medicine|January 23, 2020
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemiaEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogsXavier Leleu, Jacob Soumerai, Aldo Roccaro, et al.Journal of Cellular and Molecular Medicine|January 17, 2020
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutationsEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.Leukemia|March 8, 2020
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.Blood Cancer Journal|February 3, 2023
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeuticsDaisuke Ogiya, Zuzana Chyra, Sigitas J Verselis, et al.Molecular Cancer Therapeutics|September 3, 2010
Discovery and characterization of novel mutant FLT3 kinase inhibitorsEllen Weisberg, Hwan Geun Choi, Rosemary Barrett, et al.British Journal of Haematology|July 17, 2019
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignanciesEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.Pageof 5